- NASDAQ:NVAX reported positive phase one trial results and is deep into its phase two trials now.
- Vaccine supply deals with the US, UK, Canada, and South Korea have led to Wall Street Analysts issuing buy ratings for the stock.
Operation Warp Speed and the race for a coronavirus vaccine has been a focal point for the entire world as we approach the first year anniversary of the virus’ initial spread. It has also grabbed the attention of investors who have been trying all year to anticipate which biotech or pharmaceutical company to buy shares of. Novavax (NASDAQ:NVAX) investors have been on a wild ride this year with the 52-week range starting at $3.54 and rising as high as $189.40. The news of rival AstraZeneca (NYSE:AZN) temporarily halting its phase three trials combined with positive results from Novavax’s own trials has caused the stock to spike another 25% over the past week.
Novavax still lags behind some of its competitors like the aforementioned AstraZeneca, as well as Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) who are all either about to start or are into phase three of their respective clinical trials. The Maryland based firm may have to settle for being a supplier of a second wave of vaccines – even though it does already have established contracts to provide vaccines to several countries around the world.
NVAX stock news
Where the stock goes from here is anyone’s guess. The volatility of biotech stocks fluctuates as soon as any positive or negative trial results are issued. One saving grace for Novavax is that it does have other products it is working on that can act as additional revenue streams for the future. NanoFlu, a flu vaccine, is a potential boon for the over 65 population that is hardest hit by seasonal viruses. Novavax will have to prove that its COVID-19 vaccine has the efficacy results to be mentioned alongside the other biotech heavy hitters – if they can, the stock could see another rise up to its previously lofty levels.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD failed just ahead of the 200-day SMA
Finally, AUD/USD managed to break above the 0.6500 barrier on Wednesday, extending the weekly recovery, although its advance faltered just ahead of the 0.6530 region, where the key 200-day SMA sits.
EUR/USD met some decent resistance above 1.0700
EUR/USD remained unable to gather extra upside traction and surpass the 1.0700 hurdle in a convincing fashion on Wednesday, instead giving away part of the weekly gains against the backdrop of a decent bounce in the Dollar.
Gold keeps consolidating ahead of US first-tier figures
Gold finds it difficult to stage a rebound midweek following Monday's sharp decline but manages to hold above $2,300. The benchmark 10-year US Treasury bond yield stays in the green above 4.6% after US data, not allowing the pair to turn north.
Bitcoin price could be primed for correction as bearish activity grows near $66K area
Bitcoin (BTC) price managed to maintain a northbound trajectory after the April 20 halving, despite bold assertions by analysts that the event would be a “sell the news” situation. However, after four days of strength, the tables could be turning as a dark cloud now hovers above BTC price.
Bank of Japan's predicament: The BOJ is trapped
In this special edition of TradeGATEHub Live Trading, we're joined by guest speaker Tavi @TaviCosta, who shares his insights on the Bank of Japan's current predicament, stating, 'The BOJ is Trapped.'